公开(公告)号：US20190388471A1

公开(公告)日：2019-12-26

申请号：US16435257

申请日：2019-06-07

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Carl H. June ,  David L. Porter ,  Marcela Maus ,  Mariusz Wasik ,  Saar Gill ,  Joseph A. Fraietta ,  Marco Ruella ,  John Byrd ,  Jason Dubovsky ,  Amy Johnson ,  Natarajan Muthusamy ,  Saad Kenderian ,  Joan Mannick ,  David Jonathan Glass ,  Leon Murphy ,  Jennifer Brogdon ,  William Raj Sellers

IPC: A61K35/17 ,  A61K39/395 ,  A61K31/519 ,  A61K45/06 ,  C07K14/725 ,  A61K31/436 ,  A61K31/53 ,  C12N5/0783 ,  C07K16/28

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

公开(公告)号：US10287354B2

公开(公告)日：2019-05-14

申请号：US15105074

申请日：2014-12-19

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N9/90 ,  C07K14/74

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20180312595A1

公开(公告)日：2018-11-01

申请号：US15726703

申请日：2017-10-06

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Saar Gill ,  David Jonathan Glass ,  Saad Kenderian ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  David L. Porter ,  Marco Ruella ,  Yongqiang Wang ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K39/00 ,  C12N5/0783 ,  C07K16/24

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.